A phase II clinical trial demonstrated that a new type of treatment for genital herpes, an immunotherapy called GEN-003, may reduce the activity of the virus and the number of days with recurrent herpes....

Cambridge, Mass. biopharmaceutical company, Genocea Biosciences, Inc., announced this week positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment...